A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 219 participants.
Also called NCT02097277
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 219 participants
- Sponsor
- Registry
-
NCT02097277
-
- Other papers using this trial's data
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT02097277. Randomized; double masking; primary purpose treatment. Start 2014-04-15 (actual); primary completion 2015-09-22 (actual). Results posted on 2019-05-09.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
- Condition
- Diabetes Mellitus Type 2
- Intervention (Biological)
- BMS-986036
- Intervention (Biological)
- Placebo (Matching with BMS-986036)
- Lead sponsor
- Bristol-Myers Squibb
Record details
- Record id
cardio:ct-nct02097277- Content hash
65328b5f9fd707fa29d07420506442f45a9196f4a055b0244a74c26e4e435180